[1] Fuster D, Samet JH. Alcohol use in patients with chronic liver disease. N Engl J Med, 2018, 379(13): 1251-1261. [2] Chen S, Zhou J, Wu X, et al. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int, 2021, 15(3): 611-620. [3] An L, Wirth U, Koch D, et al. The role of gut-derived lipopolysaccharides and the intestinal barrier in fatty liver diseases. J Gastrointest Surg, 2022, 26(3): 671-683. [4] N D Tommaso, A Gasbarrini, Fr Ponziani. Intestinal barrier in human health and disease. Int J Env Res Pub He, 2021, 18(23). [5] Paradis T, Bègue H, Basmaciyan L, et al. Tight junctions as a key for pathogens invasion in intestinal epithelial cells. Int J Mol Sci, 2021, 22(5): 2506. [6] Zhuang Y, Wu H, Wang X, et al. Resveratrol attenuates oxidative stress-induced intestinal barrier injury through PI3K/Akt-Mediated Nrf2 signaling pathway. Oxid Med Cell Longev, 2019, 2019: 7591840. [7] Ulasov AV, Rosenkranz AA, Georgiev GP, et al. Nrf2/Keap1/ARE signaling: towards specific regulation. Life Sci, 2022, 291: 120111. [8] 焦新峰;鲁翔;刘正霞; 白介素-22在慢性代谢性疾病中的研究进展. 中华老年多器官疾病杂志, 2020(11 vo 19): 877-880. [9] Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov, 2014, 13(1): 21-38. [10] 王烁, 卿笃信. 白细胞介素-22在酒精性肝病中作用的研究进展. 国际消化病杂志, 2020, 40(1): 8-11+15. [11] Xiang X, Hwang S, Feng D, et al. Interleukin-22 in alcoholic hepatitis and beyond. Hepatol Int, 2020, 14(5): 667-676. [12] Patnaude L, Mayo M, Mario R, et al. Mechanisms and regulation of IL-22-mediated intestinal epithelial homeostasis and repair. Life Sci, 2021, 271: 119195. [13] 宋晓改, 李三强, 代新华, 等. 热休克蛋白70在小鼠酒精性肝纤维化过程中的表达. 中国临床药理学杂志, 2021, 37(1): 56-58+62. [14] 徐洪芹;高沿航; Liver International|亚洲地区酒精性肝病的流行特征(2000年—2020年). 临床肝胆病杂志, 2022(07 vo 38): 1625. [15] Lackner C, Tiniakos D. Fibrosis and alcohol-related liver disease. J Hepatol, 2019, 70(2): 294-304. [16] 吴慕青;李昂;符娟;李光海;李金谦;吴涛; 酒精性肝病啮齿动物模型建立的研究进展. 中国热带医学, 2022(10 vo 22): 984-990. [17] Meng YX, Zhao R, Huo LJ. Interleukin-22 alleviates alcohol-associated hepatic fibrosis, inhibits autophagy, and suppresses the PI3K/AKT/mTOR pathway in mice. Alcohol Clin Exp Res, 2023, 47(3): 448-458. [18] 宋晓改, 李三强, 文馨, 等. 解整合素-金属蛋白酶9在小鼠酒精性肝纤维化过程中的表达. 胃肠病学和肝病学杂志, 2020, 29(7): 810-813+817. [19] Szabo G, Mandrekar P, Petrasek J, et al. The unfolding web of innate immune dysregulation in alcoholic liver injury. Alcohol Clin Exp Res, 2011, 35(5): 782-786. [20] Suzuki T. Regulation of the intestinal barrier by nutrients: the role of tight junctions. Anim Sci J, 2 020, 91(1): e13357. [21] Wang Y, Tong J, Chang B, et al. Effects of alcohol on intestinal epithelial barrier permeability and expression of tight junction-associated proteins. Mol Med Rep, 2014, 9(6): 2352-2356. [22] Tan H K, Yates E, Lilly K, et al. Oxidative stress in alcohol-related liver disease. World J Hepatol, 2020, 12(7): 332-349. [23] Kong X, Feng D, Mathews S, et al. Hepatoprotective and anti-fibrotic functions of interleukin-22: therapeutic potential for the treatment of alcoholic liver disease. J Gastroenterol Hepatol, 2013, 28 Suppl 1(0 1): 56-60. [24] Ni YH, Huo LJ, Li TT. Antioxidant axis Nrf2-keap1-ARE in inhibition of alcoholic liver fibrosis by IL-22. World J Gastroenterol, 2017, 23(11): 2002-2011. [25] 李慕聪. IL-22在组织器官修复再生过程中的作用. 中华微生物学和免疫学杂志, 2021, 41(5): 400-405. |